Fennec Pharmaceuticals Inc. Common Stock (FENC) Stock Price
FENCStock
$9.98+15.51%52W
Market Cap$349.97M
P/E—
PEG Ratio1.47
Div yield—
Beta1.21
FENC Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)49.77%
Price vs S&P 500 (4W)-7.20%
PEG Ratio1.47
VGM Score60.98
FENC Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $0.02 | $0.05 | +127.27%(+$0.03) | |
| Q1 2026 | -$0.02 | $0.01 | +159.99%(+$0.03) | |
| Q4 2025 | $0.04 | -$0.10 | -350.25%(-$0.14) | |
| Q3 2025 | -$0.03 | -$0.02 | +20.00%(+$0.01) | |
| Q2 2025 | -$0.03 | -$0.11 | -266.67%(-$0.08) |
FENC Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.23
4.17
4.17
4.17
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
FENCFennec Pharmaceuticals Inc. Common Stock | D | A | B | 5.9x | 33.8% | 93.7% | — | $9.98 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
About Fennec Pharmaceuticals Inc. Common Stock
Fennec Pharmaceuticals is a biopharmaceutical company commercializing PEDMARK, a novel formulation designed to prevent cisplatin-induced hearing loss in children undergoing chemotherapy. The company addresses a significant side effect of cancer treatment with a first-in-class therapeutic approach. Operations are based in the United States.